Gilead stops phase 3 TIGIT trial, doubling down on other studies and pumping $320M into partner Arcus

Arcus Biosciences and Gilead Sciences are rethinking their TIGIT strategy. Gilead is stopping a phase 3 lung cancer TIGIT clinical trial—and walking away from another project—but reaffirming its commitment to Arcus by pumping a further $320 million into the biotech.